Drug Profile
Grass-pollen allergy immunotherapy sublingual - Lofarma
Alternative Names: LAIS® Grass TabletsLatest Information Update: 05 Jan 2023
Price :
$50
*
At a glance
- Originator Lofarma S.p.A
- Class Allergens; Antiallergics; Plant allergy immunotherapies
- Mechanism of Action Immunosuppressants; T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Allergic rhinoconjunctivitis
Most Recent Events
- 02 Jan 2023 Phase II development is still ongoing for Allergic rhinoconjunctivitis in Italy (Sublingual, Spray)
- 05 Dec 2020 Lofarma completes a phase II trial in Allergic rhinoconjunctivitis in Italy (EudraCT2018-004472-35)
- 12 Sep 2019 Lofarma initiates enrolment in a phase III trial for Allergic rhinoconjunctivitis in Italy (Sublingual) (EudraCT2019-001532-65)